Skip to main content
NRXP
NASDAQ Life Sciences

DARPA Awards $11M Prime Contract to NRx Defense for Robotic TMS Depression Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.985
Mkt Cap
$126.424M
52W Low
$1.62
52W High
$5.055
52W Position info
84% above low
Off High info
41% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NRXP sits 84% above its 52-week low of $1.62.

Summary

NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, has been awarded an initial $11.18 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101 for treatment-resistant depression. The contract has an aggregate value of approximately $11.2 million, with $6.7 million initially obligated and an 18-month performance period. The SPARC-TMS trial has received FDA approval and will begin enrolling patients at Harvard's McLean Hospital, Arizona State University, and HOPE Therapeutics, with military hospitals affiliated. This is a material step forward from the July 8-K, which only noted DARPA selection to negotiate a potential award. The contract provides non-dilutive funding and validates the company's defense-focused strategy, while the trial could serve as an FDA registration study for NRX-101 in a much larger patient population. The company remains in a going-concern position with a $16.5 million Q2 net loss, so this award meaningfully supports its cash runway. Watch for enrollment updates and any additional DARPA funding tranches.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The contract has an aggregate value of approximately $11.2 million, with $6.7 million initially obligated and an 18-month performance period.

At the time of this announcement, NRXP was trading at $2.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.4M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.22 info
Change: -$0.7598 (-25%) info
Market Cap: $98.281M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.22 info
Change: -$0.330 (-13%) info
Market Cap: $98.281M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.22 info
Change: -$0.640 (-22%) info
Market Cap: $98.281M info
NRXP
Sep 15, 2026, 9:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.35
Real-time Price: $2.22 info
Change: -$1.13 (-34%) info
Market Cap: $98.281M info
NRXP
Sep 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.42
Real-time Price: $2.22 info
Change: -$1.20 (-35%) info
Market Cap: $98.281M info